Brief: Sernova Biotherapeutics Receives FDA Clearance For Ind Application For Its Cell Pouch Bio-Hybrid Organ With Autograft Thyroid Cells In Patients With Hypothyroidism
03/03/2025 14:52
March 3 (Reuters) - Sernova Corp SVA.TO: SERNOVA BIOTHERAPEUTICS RECEIVES FDA CLEARANCE FOR IND APPLICATION FOR ITS CELL POUCH BIO-HYBRID ORGAN WITH AUTOGRAFT THYROID CELLS IN PATIENTS WITH HYPOTHYROIDISM Source text: ID:nGNX5wy36w Further company coverage: SVA.TO (Reuters.Briefs@thomsonreuters.com)
Recent news on Sernova Biotherapeutics
See all newsBrief: Seraxis And Sernova Announce Appointment Of Former FDA Medical Officer Dr. Patricia Beaston As Chief Medical Officer Of Seraxis And Post Merger Betanova Biotherapeutics
Brief: Sernova Appoints Jonathan Rigby As Interim Chair
Brief: Sernova Biotherapeutics Provides Positive Interim Data From Ongoing Phase 1/2 Clinical Trial Of Cell Pouch Bio-Hybrid Organ In Patients Living With Type 1 Diabetes
Brief: Sernova Biotherapeutics Secures $4 Million Loan To Further Advance Its Clinical Development Plans
Brief: Sernova Biotherapeutics Inc Study Is On Track To Meet Key Clinical Trial Endpoints